REGN

Regeneron Pharmaceuticals, Inc.

Next est. report 2026-10-28 · BMO

Loading…

Loading chart…

Overview

Regeneron Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines. Its key products include EYLEA HD fo

Regeneron Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines. Its key products include EYLEA HD for eye diseases, Dupixent for inflammatory conditions, and Libtayo for cancer. Dupixent, a significant revenue driver, is commercialized through a collaboration with Sanofi. Regeneron maintains a broad and diverse pipeline, actively investing in R&D for areas like obesity, rare diseases, and complement-mediated conditions.

Search Keywords Brand Product

Dupixent
EYLEA HD
Libtayo
Cemdisiran
Lynozyfic
Olatorepatide
Garetosmab
Otarmeni
Praluent
Evkeeza
ARCALYST
Ebola antibodies
biopharmaceutical research
drug development
antibody engineering
genetics center
rare disease treatment
oncology pipeline
immunology drugs
obesity medication
ophthalmology treatments
complement-mediated diseases
generalized myasthenia gravis treatment
paroxysmal nocturnal hemoglobinuria
fibrodysplasia ossificans progressiva
multiple myeloma therapy

Search Keywords Event Phrases

Regeneron Q2 2026 earnings
cemdisiran FDA decision
EYLEA HD prefilled syringe approval
PNH registrational data
FOP FDA decision
EASD Olatorepatide data

Search Keywords Policy Regulatory

FDA approval
EMA approval
drug pricing regulations
biosimilar competition

What They Do (Plain English & Analogies): Regeneron Pharmaceuticals is like a specialized farm that grows new medicines. Instead of crops, they grow new treatments for many different diseases, ranging from eye conditions that can cause blindness, to skin problems like eczema, to serious illnesses like cancer and rare genetic disorders. They discover, develop, and manufacture these medicines, and then bring them to patients around the world. They often work with other big pharmaceutical companies to help distribute and further develop these treatments.
Very Brief History: Regeneron Pharmaceuticals, Inc. was founded in 1988 in Tarrytown, New York. Over the decades, it has evolved into a global biopharmaceutical leader, known for its proprietary drug discovery platforms and successful collaborations, notably with Sanofi, which has been instrumental in developing blockbuster drugs like Dupixent. The company focuses on discovering, inventing, developing, manufacturing, and commercializing medical treatments for a wide array of illnesses.
"Street Stereotype": Regeneron is generally perceived by investors and analysts as an established, innovation-driven biopharmaceutical company with a robust and diverse pipeline. It's seen as a leader in leveraging cutting-edge research, particularly in genomics and antibody engineering, to develop high-margin treatments for complex and rare diseases. However, it also faces scrutiny regarding increasing competition from biosimilars and other emerging therapies, as well as ongoing regulatory and reimbursement challenges.
Subsidiaries On Linked In*: {"subsidiaries":[]}
Customer Sectors & Example Clients: Customer sectors include healthcare providers (such as ophthalmologists, dermatologists, pulmonologists, oncologists, allergists, ENTs, neurologists, and rare disease specialists), hospitals, and ultimately, patients suffering from various conditions. While not direct 'clients' in a traditional sense, key partners and collaborators include Sanofi (for products like Dupixent, Kevzara, Praluent), Bayer (for EYLEA outside the U.S.), and the U.S. government (for products like Inmazeb and REGEN-COV, and Ebola antibodies).
New Customers / Segments They'Re Targeting: Regeneron is actively targeting several new customer segments and expanding into new markets. For Dupixent, they are pursuing further penetration of existing indications, expansion into additional age groups, and international growth. EYLEA HD is focused on continued uptake in wet AMD, DME, DR, and RVO, with a new prefilled syringe enhancement expected to drive further adoption. Libtayo is targeting stronger adoption in non-melanoma skin cancer (including adjuvant cutaneous squamous cell carcinoma) and increased penetration in non-small cell lung cancer. New drug candidates are targeting patients with generalized myasthenia gravis (cemdisiran), fibrodysplasia ossificans progressiva (garetosmab), paroxysmal nocturnal hemoglobinuria (cemdisiran/pozelimab), and earlier lines of therapy for multiple myeloma and systemic light chain amyloidosis (Lynozyfic). In the obesity space, they are targeting patients with obesity, and those with obesity and type 2 diabetes, potentially with comorbid hypercholesterolemia (olatorepatide and combinations). They are also advancing Factor XI inhibitors for coagulation disorders, including venous thromboembolism prevention and stroke prevention in atrial fibrillation, and have earlier-stage programs for metabolic dysfunction-associated steatohepatitis (MASH) and postural orthostatic tachycardia syndrome (POTS). Additionally, they are launching Otarmeni for children with genetic hearing loss.
Supply Chain And Sourcing Geographies: Regeneron operates a bulk manufacturing facility in Limerick, Ireland, which had a temporary interruption but resumed normal production levels as of the end of the second quarter of 2026. The company also works with multiple contract manufacturers for products such as the EYLEA HD prefilled syringe. Specific sourcing geographies for raw materials or other components are not explicitly detailed in the provided information, but a global biopharmaceutical company typically maintains a diversified supply chain.
Sales Geographies And Expansion Plans: Regeneron currently sells its products in the United States (e.g., EYLEA HD, EYLEA, Libtayo, Lynozyfic, Evkeeza, ARCALYST, Inmazeb, ZALTRAP, Kevzara, REGEN-COV). Globally, or outside the U.S., products like Dupixent are sold through the Sanofi collaboration, and EYLEA through the Bayer collaboration. The company has plans to expand sales into new geographies, notably with cemdisiran, where regulatory submissions have been accepted for review by both the FDA (U.S.) and the EMA, with a European Commission decision anticipated in the second half of 2027. Dupixent also has continued international growth opportunities. Regeneron is also working with the U.S. government and international health organizations to deliver potential new treatments for Ebola virus outbreaks, specifically mentioning the Democratic Republic of the Congo.
How Key Themes May Help/Hurt: Regeneron may benefit from the 'Biotech '26: Established Pharma' theme by leveraging its cutting-edge research in genomics and antibody engineering, positioning it at the forefront of innovation in treating complex diseases. Its robust pipeline, particularly in rare disease treatments and therapies targeting niche markets (e.g., FOP, gMG, PNH), offers high-margin opportunities and potential blockbuster drugs. Strategic partnerships, such as its long-standing collaboration with Sanofi, enable portfolio expansion and enhance research capabilities, driving long-term growth. Conversely, the company may be hurt by increased competition from emerging biotech companies and generic drug manufacturers, as seen with the anticipated aflibercept 2-milligram biosimilar launches, which could erode market share and pressure pricing strategies. Regulatory uncertainties and potential shifts in healthcare policies could impact drug approval timelines and reimbursement rates, posing risks to revenue growth for new products like cemdisiran and garetosmab. While not a primary focus of the transcript, broader market volatility and economic uncertainties could also affect R&D investment and delay commercialization of new therapies.

3 Main Long-Term Bull Details

Deep and Diverse Pipeline: Regeneron boasts approximately 50 active clinical programs and many rapidly advancing preclinical candidates across multiple therapeutic areas, including hem/onc, anticoagulation, complement-mediated diseases, immunology, and obesity, reducing reliance on any single program and offering numerous future value drivers.
Proven R&D and Commercialization Engine: The company has a demonstrated ability to repeatedly discover, develop, and deliver important medicines, exemplified by the success of Dupixent (9 FDA-approved indications, $6 billion quarterly sales) and the strong uptake of EYLEA HD and Libtayo, indicating a highly productive and effective operational infrastructure.
Strategic Capital Allocation and Financial Strength: Regeneron prioritizes investing in its science while actively evaluating external opportunities, supported by $15.1 billion in cash and marketable securities (net of debt) as of Q2 2026, positioning it well to capitalize on compelling M&A or licensing deals and drive long-term shareholder value.

3 Main Long-Term Bear Details

Intensifying Competition and Biosimilar Pressure: The market for key products like EYLEA is facing increased competition from biosimilars (e.g., aflibercept 2-milligram biosimilars), and other therapeutic areas are becoming crowded, potentially leading to market share erosion and pricing pressure.
Regulatory Hurdles and Approval Delays: Delays in regulatory decisions for product enhancements (e.g., EYLEA HD prefilled syringe) or new drug applications (e.g., cemdisiran, garetosmab) can impact launch timelines and revenue realization, introducing uncertainty into the company's growth trajectory.
Dependence on Key Collaborations and Product Performance: A significant portion of revenue and pipeline success is tied to collaborations (e.g., Sanofi for Dupixent, Bayer for EYLEA OUS). Any issues with these partnerships or a slowdown in growth for blockbuster products could materially impact financial performance.

Competitors And Differentiation: Regeneron faces competition across its therapeutic areas. In ophthalmology, EYLEA and EYLEA HD compete with other anti-VEGF medicines and anticipated aflibercept 2-milligram biosimilar launches. For complement-mediated diseases, cemdisiran competes with C5 antibodies like ravulizumab and eculizumab, and FcRn approaches such as VYVGART for generalized myasthenia gravis. In the obesity market, olatorepatide and trevogrumab combinations compete with GLP-1/GIP receptor agonists like tirzepatide and semaglutide. Regeneron differentiates itself through: 1) a broad and diverse pipeline of approximately 50 active clinical programs, reducing reliance on any single asset. 2) Developing next-generation products with enhanced profiles, such as EYLEA HD's differentiated dosing flexibility and the EYLEA HD prefilled syringe, or long-acting IL-13 antibodies. 3) Focusing on novel mechanisms of action, often informed by genetic insights, to directly address disease pathology (e.g., MASH program). 4) Offering differentiated efficacy, safety, and convenience, such as cemdisiran's subcutaneous dosing and efficacy without complete complement inhibition. 5) Exploring combination therapies to address comorbidities or mitigate side effects, like olatorepatide with Praluent for hypercholesterolemia or trevogrumab with semaglutide to preserve muscle mass.
Recent Performance & What The Market'S Focused On: Regeneron delivered a strong second quarter of 2026, with total revenues up 17% to $4.3 billion and non-GAAP earnings per share up 11% to $14.29 compared to the prior year. Dupixent, EYLEA HD, and Libtayo all achieved new all-time highs for quarterly net sales. EYLEA HD U.S. net sales were nearly $600 million, up 52% year-over-year, and now comprise approximately 60% of the U.S. retinal franchise net sales. Libtayo global net sales reached nearly $500 million, up 29% year-over-year. The market is focused on several key upcoming milestones: an FDA decision in November for cemdisiran in generalized myasthenia gravis, potential FDA approval for the EYLEA HD prefilled syringe by year-end, registrational data for cemdisiran/pozelimab in PNH in Q4 2026, 26-week data for the C5 approach in geographic atrophy in Q4 2026, an FDA decision in August for garetosmab in FOP, and Phase III study initiations for the obesity portfolio later this year.

Revenue Segments And Estimated Mix: Sanofi Collaboration Revenue (primarily Dupixent) — Mix: ~51%; Source: Q2 2026 earnings transcript; Trend: Up 59% year-over-year, reached an all-time high
U.S. EYLEA HD & EYLEA Net Sales — Mix: ~23%; Source: Q2 2026 earnings transcript; Trend: Combined up 7% quarter-over-quarter; EYLEA HD up 52% YoY, EYLEA down 45% YoY due to conversion to EYLEA HD and competition
Libtayo Worldwide Net Sales — Mix: ~11%; Source: Q2 2026 earnings transcript; Trend: Up 29% year-over-year on a constant currency basis
Bayer Collaboration Revenue (EYLEA OUS) — Mix: ~6%; Source: Q2 2026 earnings transcript
Other Revenue (including Ilaris royalties, ARCALYST profits) — Mix: ~4%; Source: Q2 2026 earnings transcript; Trend: Up 5% year-over-year
Evkeeza Net Sales — Mix: ~1%; Source: Q2 2026 earnings transcript; Trend: Up 29% year-over-year
Product Brands: EYLEA
Dupixent
Libtayo
Praluent
REGEN-COV
Kevzara
Inmazeb
ARCALYST
ZALTRAP
EYLEA HD
Lynozyfic
Evkeeza
Otarmeni
Garetosmab
Cemdisiran
Pozelimab
Olatorepatide
Trevogrumab
Cenvacibart
Amrecibart
Ubamatamab

Bull / Bear Details

Regeneron maintains a strong investment profile as of August 27, 2026, driven by robust commercial performance of key products like Dupixent, EYLEA HD, and Libt

Thesis

Regeneron maintains a strong investment profile as of August 27, 2026, driven by robust commercial performance of key products like Dupixent, EYLEA HD, and Libtayo. Its deep and diverse pipeline, with numerous near-term catalysts across immunology, oncology, and rare diseases, promises future growth. Strategic capital allocation and successful collaborations further bolster the bull case, despite increasing biosimilar competition for EYLEA and inherent risks in drug development and competitive markets. The bull case appears more compelling.

Bull case

Regeneron's commercial portfolio demonstrates significant momentum, with Dupixent, EYLEA HD, and Libtayo achieving record sales and double-digit growth in Q2 2026. EYLEA HD continues its strong conversion from EYLEA, now comprising 60% of U.S. franchise sales, with further adoption expected from the prefilled syringe approval by year-end 2026. This strong performance across market-leading brands underpins robust revenue generation.
The company boasts a broad and highly productive pipeline with approximately 50 active clinical programs. Key near-term catalysts include FDA decisions for cemdisiran in gMG (November 2026) and garetosmab in FOP (August 2026), along with registrational data for cemdisiran/pozelimab in PNH (Q4 2026). Advancements in long-acting IL-13 antibodies and obesity programs further diversify future growth drivers.
Regeneron's strategic capital allocation prioritizes internal R&D while actively pursuing external opportunities with valuation discipline. The highly successful, nearly two-decade-long collaboration with Sanofi continues to drive Dupixent's growth, with productive discussions underway for potential expansion into Dupixent follow-on programs, leveraging joint development and commercialization expertise.

Bear case

Increased competition and product cannibalization pose headwinds, particularly for the EYLEA franchise. EYLEA U.S. net sales declined significantly by 45% year-over-year, driven by conversion to EYLEA HD and anticipated launches of multiple aflibercept 2mg biosimilars in the second half of 2026. This will likely continue to pressure market share and revenue for the original EYLEA product.
Regulatory uncertainties and inherent development risks persist across the extensive pipeline. Delays in the EYLEA HD prefilled syringe approval due to FDA changes highlight potential regulatory hurdles. While the pipeline is diverse, not every program will succeed, as evidenced by the recent fianlimab setback in oncology, underscoring the challenges of drug development.
The competitive landscape in emerging therapeutic areas, such as obesity and gMG, presents challenges. While Regeneron aims for differentiation with its olatorepatide program and cemdisiran in gMG, these are crowded markets with established players and numerous new entrants. Lynozyfic's modest growth in its current late-line setting also indicates market penetration difficulties.

Bull / Bear Case

Bear Case: Increased competition and product cannibalization pose headwinds, particularly for the EYLEA franchise. EYLEA U.S. net sales declined significantly by 45% year-over-year, driven by conversion to EYLEA HD and anticipated launches of multiple aflibercept 2mg biosimilars in the second half of 2026, which is expected to further pressure market share and revenue for the original EYLEA product. Regulatory uncertainties and inherent development risks persist across the extensive pipeline. Delays in the EYLEA HD prefilled syringe approval due to FDA changes highlight potential regulatory hurdles. While the pipeline is diverse, not every program will succeed, as evidenced by the recent fianlimab setback in oncology, underscoring the challenges of drug development. The competitive landscape in emerging therapeutic areas, such as obesity and generalized myasthenia gravis (gMG), presents challenges. While Regeneron aims for differentiation with its olatorepatide program and cemdisiran in gMG, these are crowded markets with established players and numerous new entrants. Lynozyfic's modest growth in its current late-line setting also indicates market penetration difficulties.
Bull Case: Regeneron's commercial portfolio is demonstrating significant momentum, with Dupixent, EYLEA HD, and Libtayo achieving record sales and double-digit growth in Q2 2026. EYLEA HD continues its strong conversion from EYLEA, now comprising 60% of U.S. franchise sales, with further adoption expected from the prefilled syringe approval by year-end 2026. This robust performance across market-leading brands underpins strong revenue generation. The company boasts a broad and highly productive pipeline with approximately 50 active clinical programs and numerous near-term catalysts, including FDA decisions for cemdisiran in gMG (November 2026) and garetosmab in FOP (August 2026), along with registrational data for cemdisiran/pozelimab in PNH (Q4 2026). Advancements in long-acting IL-13 antibodies and obesity programs further diversify future growth drivers. Additionally, the full repayment of the Sanofi development balance is expected to significantly boost Regeneron's reported share of collaboration profits starting in Q3 2026, enhancing overall revenue growth.
More Compelling & Why: Bull. Despite some valuation metrics suggesting it's fairly valued, a discounted cash flow analysis indicates Regeneron may be significantly undervalued. The strongest argument for the bull case is the robust commercial momentum of key products (Dupixent, EYLEA HD, Libtayo) combined with a deep and diverse pipeline offering numerous near-term catalysts and a significant boost in Sanofi collaboration revenue. My view would flip to Bear if there were significant and unexpected late-stage clinical trial failures or a much more severe-than-anticipated impact from EYLEA biosimilar competition that EYLEA HD cannot offset, leading to a sustained decline in overall revenue growth.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
FDA Approval of Garetosmab (Pasatru) for Fibrodysplasia Ossificans Progressiva (FOP)	This approval for an ultra-rare genetic disorder provides a new treatment option and represents a significant market expansion for Regeneron's rare disease portfolio, contributing to revenue diversification and long-term growth.	Confirmation of commercial launch plans, initial sales figures, and payer coverage for Pasatru in adults with FOP. The approval was announced on August 19, 2026.	Approval received on August 19, 2026, is a bullish signal, indicating successful regulatory execution and a new revenue stream.	Regeneron press releases, SEC filings (Form 10-Q for Q3 2026), medical news outlets. The approval was announced on August 19, 2026.	Google Trends: 'Pasatru FOP', 'garetosmab FOP'. Patient advocacy group websites (e.g., IFOPA).	IQVIA/Symphony Health: Pasatru new prescriptions, market share. EvaluatePharma: Sales forecasts for Pasatru.
Registrational Data Readout for Cemdisiran + Pozelimab in Paroxysmal Nocturnal Hemoglobinuria (PNH)	Positive registrational data would support a new, potentially differentiated subcutaneous combination therapy for PNH, offering improved disease control and convenience, expanding Regeneron's complement-mediated disease franchise.	Topline results from the registrational study, specifically regarding non-inferiority to eculizumab on intravascular hemolysis control and transfusion avoidance.	Positive data demonstrating non-inferiority and/or improved disease control/convenience = bullish signal. Negative data or significant safety concerns = bearish signal.	Regeneron press releases, medical conference presentations, ClinicalTrials.gov (for trial NCT05133531 or related PNH studies). Expected in Q4 2026.	ClinicalTrials.gov: Updates on PNH study completion. Reddit: r/PNH patient forums.	EvaluatePharma: PNH market analysis, competitive landscape.
Initiation of Phase III Studies for Olatorepatide in Obesity	The commencement of Phase III trials for olatorepatide signifies Regeneron's formal entry into the highly lucrative and rapidly expanding obesity market, with a dual GLP-1/GIP receptor agonist that has shown promising efficacy and tolerability.	Official announcements from Regeneron regarding the initiation of Phase III studies for olatorepatide in patients with obesity and those with obesity and type 2 diabetes. Expected later in 2026.	Initiation of Phase III studies later in 2026 = bullish signal, indicating progress in a high-potential pipeline area. Delays or changes in development plans = bearish signal.	Regeneron press releases, ClinicalTrials.gov, SEC filings. Expected later in 2026.	Google Trends: 'olatorepatide obesity', 'Regeneron obesity drug'. Industry news on GLP-1/GIP agonists.	EvaluatePharma: Obesity market forecasts, competitive pipeline. Clinical trial intelligence platforms.
FDA Decision for Cemdisiran in Generalized Myasthenia Gravis (gMG)	Potential approval of cemdisiran would introduce a highly differentiated C5 siRNA therapy for gMG, offering convenient quarterly subcutaneous dosing and potentially capturing significant market share in a growing category.	The FDA's final decision on the New Drug Application (NDA) for cemdisiran in gMG. The target action date is November 2026.	Approval in November 2026 = bullish signal, indicating a new product launch and competitive advantage. Complete Response Letter (CRL) or delay = bearish signal.	Regeneron press releases, FDA announcements, SEC filings. Target action date is November 2026.	ClinicalTrials.gov: NIMBLE trial status updates. Reddit: r/myastheniagravis discussions.	EvaluatePharma: Cemdisiran sales forecasts, market penetration. IQVIA/Symphony Health: Competitor (e.g., VYVGART) prescription trends.
EYLEA HD Prefilled Syringe Approval	Approval of the prefilled syringe would enhance EYLEA HD's convenience and ease of use for healthcare providers, further driving adoption and strengthening its competitive position against biosimilars and other anti-VEGF therapies.	Announcement of FDA approval for the EYLEA HD prefilled syringe. Regeneron expects approval before the end of 2026.	Approval before year-end 2026 = bullish signal, indicating improved product offering and continued market leadership. Delay or rejection = bearish signal.	Regeneron press releases, FDA announcements, SEC filings. Expected before the end of 2026.	Google Trends: 'EYLEA HD prefilled syringe'. Industry news sites covering ophthalmology.	IQVIA/Symphony Health: EYLEA HD unit demand, market share trends post-PFS launch.

Key Reported Metrics, Reratings Triggers & Results3 rows

This metric is critical due to the significant year-over-year decline and anticipated biosimilar competition in the second half of 2026. The pace of decline wil

Upcoming print · 2026-10-28

Key reported metrics
Metric	Last period	Why it matters
EYLEA U.S. Net Sales	-45%	This metric is critical due to the significant year-over-year decline and anticipated biosimilar competition in the second half of 2026. The pace of decline will indicate the impact of competitive pressures and the success of EYLEA HD conversion.
EYLEA HD U.S. Net Product Sales	52%	EYLEA HD is Regeneron's key growth driver in ophthalmology, offsetting declines from original EYLEA. Continued strong uptake and market share gains are essential for maintaining revenue momentum and demonstrating successful product conversion and differentiation.
Sanofi Collaboration Revenue (Regeneron's share of profits)	59%	This metric is crucial as the full repayment of the Sanofi development balance will significantly boost Regeneron's reported share of collaboration profits starting in the next quarter. Investors will watch for the magnitude of this step-up and its impact on overall revenue growth.

Key Questions

Will the FDA approval and subsequent uptake of the EYLEA HD prefilled syringe by year-end be sufficient to accelerate EYLEA HD's market share gains and fully mi

Will the FDA approval and subsequent uptake of the EYLEA HD prefilled syringe by year-end be sufficient to accelerate EYLEA HD's market share gains and fully mitigate the revenue impact from EYLEA biosimilar competition over the next quarter?

Question 2: Following the anticipated November FDA approval for cemdisiran in generalized myasthenia gravis, will its differentiated profile and convenient dosing lead to a rapid and significant market share capture against existing therapies in the next quarter?
Question 3: Will Regeneron announce an expanded collaboration with Sanofi for Dupixent follow-on programs, and will the initiation of Phase III studies for olatorepatide in obesity later this year provide further validation of Regeneron's diversified pipeline and future growth prospects?

Earnings Transcript SummaryTable

2026-07-30 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Advancing and diversifying the pipeline: Management emphasized their broad, diversified, and highly productive pipeline with approximately 50 active clinical programs, highlighting near-term regulatory and clinical milestones for C5 complement programs (cemdisiran, pozelimab), Factor XI, linvoseltamab, and their obesity portfolio. They believe this pipeline will create substantial value for patients and shareholders. 2. Maximizing commercial success of key growth drivers: Regeneron is focused on driving continued growth for Dupixent, EYLEA HD, and Libtayo. This includes further penetration of existing indications, expansion into additional age groups and international markets for Dupixent, and product enhancements like the EYLEA HD prefilled syringe to drive further adoption. 3. Strategic capital allocation and external opportunities: Management reiterated their consistent framework, prioritizing investment in internal science while actively evaluating external business development options. They are disciplined on valuation and strategic fit, looking for opportunities to leverage Regeneron's expertise.	Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Regeneron delivered a strong second quarter with double-digit growth in total revenues and non-GAAP EPS, driven by robust performance from Dupixent, EYLEA HD, and Libtayo. Management expressed strong confidence in the company's long-term outlook, emphasizing a deep and diverse pipeline with significant upcoming milestones, ongoing commercial momentum, and a disciplined capital allocation strategy. The tone was optimistic, highlighting the company's ability to repeatedly discover, develop, and deliver important medicines and create sustainable value.	Prior Quarter'S Y/Y Growth By SegmentIn Q1 2026, total revenues increased 19% year-over-year. Dupixent global net sales (recorded by Sanofi) increased 33% year-over-year. EYLEA HD U.S. net sales increased 52% year-over-year. Libtayo global net sales were described as having 'strong growth' but a specific year-over-year percentage was not explicitly provided. The combined EYLEA HD and EYLEA U.S. net sales decreased 10% year-over-year in Q1 2026; a specific year-over-year growth/decline for EYLEA alone was not explicitly provided. Sanofi collaboration revenue was described as a driver of total revenue growth, but a specific year-over-year percentage was not explicitly provided. Year-over-year growth for other revenue and royalty income from Ilaris combined with share of profits from ARCALYST was not explicitly provided for Q1 2026.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Cash management and M&A strategy: An analyst questioned Regeneron's large cash on hand and Len Schleifer's past 'aversion to M&A.' Len clarified that he has 'no aversion to M&A,' but rather an 'aversion to overpaying,' emphasizing discipline in creating long-term shareholder value. 2. Expansion of Sanofi collaboration for additional assets: Analysts inquired about expanding the successful Sanofi collaboration to include additional assets, particularly Dupixent follow-on programs. Len Schleifer confirmed 'productive early discussions' with Sanofi, aiming to leverage their joint capabilities and adjust the relationship to reflect the current strengths of both companies. George Yancopoulos added that they would continue to be innovative in development. 3. EYLEA HD prefilled syringe approval timeline and manufacturing: An analyst pressed for details on the EYLEA HD prefilled syringe review, hopeful year-end approval, and the involvement of 'multiple contract manufacturers.' Len Schleifer explained that FDA leadership changes caused delays, but recent 'good conversations' and working with 'more than 2' CMOs suggest approval by year-end or sooner is possible.	Revenue SegmentsTotal revenues were up 17% year-over-year. Dupixent global net product sales (as reported by Sanofi) were up 38% year-over-year on a constant currency basis. EYLEA HD U.S. net product sales were up 52% year-over-year. Libtayo global net product sales were up 29% year-over-year on a constant currency basis. EYLEA U.S. net sales were down 45% year-over-year. Sanofi collaboration revenue reached an all-time high of $2.2 billion, with Regeneron's share of profits growing 59% versus the prior year. Other revenue increased 5% year-over-year. Royalty income from Ilaris combined with share of profits from ARCALYST increased 44% versus the prior year.

Transcript TidbitsTable

2026-07-30

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketRegeneron sees a long runway for Dupixent growth through further penetration of existing indications, expansion into additional age groups, and international growth opportunities. EYLEA HD's growth is driven by recent FDA label expansions, including wet AMD, DME, DR, and RVO, offering the broadest dosing interval in the category. Libtayo is expanding its market through strong adoption in non-melanoma skin cancers and increased penetration in non-small cell lung cancer. Lynozyfic is advancing into earlier lines of therapy with a newly initiated pivotal study in high-risk smoldering multiple myeloma and a planned Phase III study in first-line light chain amyloidosis. Cemdisiran has the potential to offer a differentiated profile for patients with generalized myasthenia gravis, representing a significant opportunity in a large and growing category. Garetosmab, if approved for FOP, would be the first treatment shown to reduce new abnormal bone formation lesions and flare-ups in patients.	About CompetitionEYLEA HD's net sales exceeding EYLEA highlights the strong conversion to Regeneron's next-generation product. However, EYLEA is facing sequential quarterly demand declines due to conversion to EYLEA HD and additional competition from multiple aflibercept 2-milligram biosimilar launches. Cemdisiran is positioned as a highly differentiated treatment option in generalized myasthenia gravis compared to C5 antibodies and other modalities, potentially offering a more convenient monthly subcutaneous regimen and improved disease control. In the obesity market, Regeneron aims to provide a fundamentally different profile by addressing comorbidities like hypercholesterolemia and preventing muscle mass loss, rather than just competing on marginal weight loss percentages. The company notes that a significant proportion of FcRn-treated patients in gMG lose efficacy over time and require switching to other therapies.	About The Broader IndustryThe company noted changes in FDA leadership and processes, impacting regulatory timelines. In MASH, Regeneron believes its siRNA programs directly address the genetic mechanisms of the disease, differentiating them from other agents that work indirectly. The evolution of obesity treatment is highlighting the increasing importance of preventing muscle mass loss, particularly in older patients with sarcopenic obesity. The company acknowledged the long-standing challenges in cancer research, noting that while incremental advances are celebrated, a cure remains elusive, and Regeneron continues to pursue diverse approaches in this difficult field.	Where Things Are HeadedRegeneron anticipates a long runway for Dupixent growth, driven by further penetration, age group expansion, and international opportunities. The company expects the launch of the EYLEA HD prefilled syringe to drive even further adoption, with approval targeted before the end of the year, and projects sequential demand growth for EYLEA HD in the low to mid-teens in Q3 and Q4 2026. Libtayo is expected to see continued growth in H2 2026 by gaining incremental share in lung cancer and driving uptake across approved CSCC stages. Multiple regulatory and clinical milestones are expected for the C5 complement programs, including an FDA decision for cemdisiran in generalized myasthenia gravis in November. Regeneron plans to initiate Phase III studies for its obesity portfolio later this year and expects to advance its long-acting IL-13 antibody to registration-enabling studies by the end of next year or early 2028. The company is engaged in productive early discussions with Sanofi for potential further collaboration on Dupixent follow-on programs. Regeneron expresses a strong commitment to its ophthalmology portfolio, aiming to deliver differentiated advances akin to EYLEA for conditions like glaucoma, thyroid eye disease, and geographic atrophy.	Updates On ThemeThe	Broader Themes EmergingGenomics and Personalized Medicine are emerging as broader themes, particularly highlighted by Regeneron's investment in its Genetics Center to redefine the understanding and treatment of diseases like MASH by directly addressing genetic mechanisms. The evolution of obesity treatment is also emerging as a theme, with a focus shifting beyond just weight loss to include the preservation of muscle mass, especially in older patients with sarcopenic obesity. The increasing focus on rare diseases and unmet medical needs is also a broader theme, as Regeneron expands its portfolio in this area.	Bullish-Leaning Quotes (Short)Regeneron delivered another strong quarter with total revenues up 17% and non-GAAP earnings per share up 11% compared to the second quarter of 2025, making our second consecutive quarter of double-digit growth on both the top and bottom lines. Dupixent, EYLEA HD and Libtayo all set new all-time highs for quarterly net sales and are carrying strong momentum into the second half of the year. I firmly believe that one of Regeneron's core strengths is that we do not rely on any single program or platform. Our pipeline is broad, diversified and highly productive. We think that we have obviously an optimal option for patients and physicians to consider. We think that we have the best efficacy cross study shown in the field.	Bearish-Leaning Quotes (Short)EYLEA U.S. net sales in the second quarter were $412 million, representing a 45% year-over-year decline and a 13% decline quarter-over-quarter, primarily driven by ongoing conversion to EYLEA HD and competitive dynamics. Looking to the second half of 2026 for EYLEA, we expect sequential quarterly demand declines in the low to mid-teens due to the factors mentioned as well as additional competition primarily from multiple aflibercept 2-milligram biosimilar launches. Despite its strong profile, we expect Lynozyfic growth to remain modest in this small late-line setting as we work to advance into earlier lines of therapy. And while not every program will succeed, we are confident that it will create many substantial value for patients and shareholders. Numerically, it did add about 5 months in PFS. And as you saw, we just missed on our primary endpoint.	HiringRegeneron has demonstrated an amazing ability to attract talent to the organization for the upcoming launch of cemdisiran in generalized myasthenia gravis.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-07-30	Regeneron reported strong Q2 2026 results with 17% revenue growth, driven by record sales for Dupixent, EYLEA HD, and Libtayo. Key pipeline catalysts include EYLEA HD prefilled syringe approval by year-end and cemdisiran FDA decision in November. The Sanofi development balance repayment will boost future collaboration revenue. Despite EYLEA's decline, the stock surged 9.66% post-earnings, significantly outperforming the SPY, indicating strong market confidence in Regeneron's commercial momentum and pipeline.	Earnings Transcript	Positive		+9.66% (vs SPY: +5.79%)

Upcoming EventsTable

No data for this section.